Eli Lilly halts trials of investigational chronic kidney disease drug
Eli Lilly has stopped trials of its investigational drug to treat chronic kidney disease for a “lack of foreseeable clinical benefit,” according to.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Eli Lilly has stopped trials of its investigational drug to treat chronic kidney disease for a “lack of foreseeable clinical benefit,” according to.
Merck & Co., got approval from the European Commission to market its combination therapy to treat metastatic urothelial cancer or bladder cancer in.
HQ Team November 18, 2023: The Food and Drug Administration (FDA) has green-lighted Astellas Pharma’s prostrate cancer drug Xtandi five weeks ahead of.
HQ Team May 14, 2023: Astellas Pharma, a Japanese drugmaker, announced that the FDA has approved its oral drug Veozah for the treatment.